HISUN(SH:600267)2016-10-28 16:00Financial Performance - Operating revenue for the first nine months rose by 9.37% to CNY 7,335,716,106.93 year-on-year[6] - Net profit attributable to shareholders surged by 599.64% to CNY 31,004,371.34 compared to the same period last year[6] - Basic earnings per share rose by 200% to CNY 0.03[7] - Total operating revenue for Q3 2016 reached ¥2,606,351,817.22, an increase of 18.6% compared to ¥2,196,519,099.39 in Q3 2015[33] - Net profit for Q3 2016 was ¥71,962,836.56, a significant recovery from a net loss of ¥8,360,188.08 in Q3 2015[35] - The company reported a total profit of ¥113,425,182.13 for Q3 2016, compared to ¥19,822,981.24 in the same quarter of the previous year, marking a growth of 471.5%[34] Assets and Liabilities - Total assets increased by 4.47% to CNY 20,031,835,300.91 compared to the end of the previous year[6] - The total liabilities increased to CNY 11,890,550,578.15 from CNY 11,009,167,992.74, representing an increase of approximately 7.99%[25] - The company's non-current assets totaled CNY 13,037,794,212.02, up from CNY 12,250,387,913.89, indicating a growth of about 6.39%[24] - The total equity attributable to shareholders decreased slightly to CNY 6,880,823,553.04 from CNY 6,919,578,264.52, a decline of approximately 0.56%[25] Cash Flow - Net cash flow from operating activities decreased by 23.79% to CNY 455,626,549.72 year-to-date[6] - The company reported a net cash flow decrease of CNY 75,379,773.06 for the first nine months of 2016, compared to a decrease of CNY 60,871,325.01 in the previous year[44] - Total cash inflow from operating activities was CNY 1,961,166,139.45, down from CNY 2,136,151,698.63 year-over-year[44] - Cash outflow from investing activities totaled CNY 562,629,926.19, significantly lower than CNY 1,110,342,896.99 in the previous year[44] - Net cash flow from financing activities was CNY 169,320,898.99, a decrease of 74% compared to CNY 662,009,677.25 in the same period last year[44] Shareholder Information - The total number of shareholders reached 26,331 by the end of the reporting period[10] - The largest shareholder, Zhejiang Haizheng Group, holds 33.22% of the shares[11] Investments and Expenditures - Development expenditures increased by 40.12% to RMB 468,170,503.11, reflecting higher spending on biopharmaceuticals, generics, and innovative drugs[14] - The company issued bonds totaling RMB 2,284,369,900.35, marking an increase of 188.30% compared to the previous period[14] - The company received financial support from its controlling shareholder, with a total of RMB 245 million principal outstanding as of the report date[14] Future Plans and Developments - The company plans to establish a joint venture with Sanofi for diabetes treatment, currently in the due diligence phase[16] - The company has not disclosed any new product developments or market expansion strategies in this report[6] Operational Challenges - The company reported a decrease in cash flow from operating activities, which may impact future liquidity and investment capabilities[21] - Operating cash flow for the first nine months of 2016 was CNY 267,787,785.56, a decrease of 22% compared to CNY 343,196,486.55 in the same period last year[44] - The company reported a net loss of CNY 126,186,729.87 after deducting non-recurring gains and losses[6]